Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline

por Sturm, Stefan, Forsberg, Anton, Nave, Stephane, Stenkrona, Per, Seneca, Nicholas, Varrone, Andrea, Comley, Robert A., Fazio, Patrik, Jamois, Candice, Nakao, Ryuji, Ejduk, Zbigniew, Al-Tawil, Nabil, Akenine, Ulrika, Halldin, Christer, Andreasen, Niels, Ricci, Benedicte
Publicado 2016

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

por Nave, Stephane, Doody, Rachelle S., Boada, Mercè, Grimmer, Timo, Savola, Juha-Matti, Delmar, Paul, Pauly-Evers, Meike, Nikolcheva, Tania, Czech, Christian, Borroni, Edilio, Ricci, Benedicte, Dukart, Juergen, Mannino, Marie, Carey, Tracie, Moran, Emma, Gilaberte, Inma, Muelhardt, Nicoletta Milani, Gerlach, Irene, Santarelli, Luca, Ostrowitzki, Susanne, Fontoura, Paulo
Publicado 2017

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

por Pagano, Gennaro, Boess, Frank G., Taylor, Kirsten I., Ricci, Benedicte, Mollenhauer, Brit, Poewe, Werner, Boulay, Anne, Anzures-Cabrera, Judith, Vogt, Annamarie, Marchesi, Maddalena, Post, Anke, Nikolcheva, Tania, Kinney, Gene G., Zago, Wagner M., Ness, Daniel K., Svoboda, Hanno, Britschgi, Markus, Ostrowitzki, Susanne, Simuni, Tanya, Marek, Kenneth, Koller, Martin, Sevigny, Jeff, Doody, Rachelle, Fontoura, Paulo, Umbricht, Daniel, Bonni, Azad
Publicado 2021